Impact of fecal microbiota transplantation with capsules on the prevention of metabolic syndrome among patients with obesity.
Diabetes
FMT
Metabolic syndrome
Obesity
Journal
Hormones (Athens, Greece)
ISSN: 2520-8721
Titre abrégé: Hormones (Athens)
Pays: Switzerland
ID NLM: 101142469
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
24
06
2020
accepted:
25
11
2020
pubmed:
10
1
2021
medline:
29
10
2021
entrez:
9
1
2021
Statut:
ppublish
Résumé
Fecal microbiota transplantation (FMT) has been studied for the treatment of metabolic syndrome with varying success. However, the possibility of utilizing FMT to prevent metabolic syndrome is to date unknown. Secondary analysis of a previously published double-blind, randomized, placebo-controlled pilot trial of FMT in obese metabolically healthy patients was conducted. Post-prandial glucose and insulin levels were measured (NCT02741518). A total of 22 patients were enrolled, 11 in each arm. There were no baseline differences in the area under the curve (AUC) of glucose or insulin in the FMT group compared to placebo. There was a significant change in glucose AUC at week 12 compared to baseline, and in the insulin AUC at week 6 compared to baseline in the FMT group vs. placebo (change in glucose AUC (mg/dl × 60 min): 579 vs 1978, p = 0.03) (change in insulin AUC (μU/ml × 60 min): 137 vs 2728, p = 0.01). These data suggest that FMT may have a potential role in preventing the development of metabolic syndrome in patients with obesity.
Sections du résumé
BACKGROUND
BACKGROUND
Fecal microbiota transplantation (FMT) has been studied for the treatment of metabolic syndrome with varying success. However, the possibility of utilizing FMT to prevent metabolic syndrome is to date unknown.
METHODS
METHODS
Secondary analysis of a previously published double-blind, randomized, placebo-controlled pilot trial of FMT in obese metabolically healthy patients was conducted. Post-prandial glucose and insulin levels were measured (NCT02741518).
RESULTS
RESULTS
A total of 22 patients were enrolled, 11 in each arm. There were no baseline differences in the area under the curve (AUC) of glucose or insulin in the FMT group compared to placebo. There was a significant change in glucose AUC at week 12 compared to baseline, and in the insulin AUC at week 6 compared to baseline in the FMT group vs. placebo (change in glucose AUC (mg/dl × 60 min): 579 vs 1978, p = 0.03) (change in insulin AUC (μU/ml × 60 min): 137 vs 2728, p = 0.01).
CONCLUSIONS
CONCLUSIONS
These data suggest that FMT may have a potential role in preventing the development of metabolic syndrome in patients with obesity.
Identifiants
pubmed: 33420959
doi: 10.1007/s42000-020-00265-z
pii: 10.1007/s42000-020-00265-z
pmc: PMC8432937
mid: NIHMS1737019
doi:
Banques de données
ClinicalTrials.gov
['NCT02741518']
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
209-211Subventions
Organisme : Medical Research Council
ID : MR/R000875/1
Pays : United Kingdom
Organisme : NCCIH NIH HHS
ID : R21 AT010956
Pays : United States
Organisme : Brigham and Women's Hospital
ID : Junior Faculty Developement Award
Références
Gastroenterology. 2012 Oct;143(4):913-6.e7
pubmed: 22728514
Lipids Health Dis. 2020 May 9;19(1):90
pubmed: 32386512
PLoS Med. 2020 Mar 9;17(3):e1003051
pubmed: 32150549
Cell Metab. 2017 Oct 3;26(4):611-619.e6
pubmed: 28978426
Circulation. 2012 Mar 6;125(9):1157-70
pubmed: 22392863
Clin Gastroenterol Hepatol. 2020 Apr;18(4):855-863.e2
pubmed: 31301451